ES2092560T3 - Proteinas inmunologicamente activas de borrelia burgdorferi, estuches de ensayo relacionados y vacuna. - Google Patents

Proteinas inmunologicamente activas de borrelia burgdorferi, estuches de ensayo relacionados y vacuna.

Info

Publication number
ES2092560T3
ES2092560T3 ES91902687T ES91902687T ES2092560T3 ES 2092560 T3 ES2092560 T3 ES 2092560T3 ES 91902687 T ES91902687 T ES 91902687T ES 91902687 T ES91902687 T ES 91902687T ES 2092560 T3 ES2092560 T3 ES 2092560T3
Authority
ES
Spain
Prior art keywords
proteins
borrelia burgdorferi
test kits
active proteins
burgdorferi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91902687T
Other languages
English (en)
Other versions
ES2092560T5 (es
Inventor
Renate Fuchs
Bettina Wilske
Vera Preac-Mursic
Manfred Motz
Erwin Soutschek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MIKROGEN MOLEKULARBIOL ENTW
Original Assignee
MIKROGEN MOLEKULARBIOL ENTW
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25888425&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2092560(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE3942728A external-priority patent/DE3942728C1/de
Priority claimed from DE4018988A external-priority patent/DE4018988C2/de
Application filed by MIKROGEN MOLEKULARBIOL ENTW filed Critical MIKROGEN MOLEKULARBIOL ENTW
Publication of ES2092560T3 publication Critical patent/ES2092560T3/es
Application granted granted Critical
Publication of ES2092560T5 publication Critical patent/ES2092560T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1207—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/804—Radioisotope, e.g. radioimmunoassay
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

PROTEINAS ACTIVAS INMUNOLOGICAS DE BORRELIA BURGDORFERI, KITS DE PRUEBA RELACIONADOS Y VACUNAS. DIVERSAS PROTEINAS INMUNOLOGICAMENTE ACTIVAS DE BORRELIA BURGDORFERI SE PRODUJERON EN MICROORGANISMOS POR TRATAMIENTO TECNOLOGICO DE GENES. PARA ELLO, SE SELECCIONARON LAS SECUENCIAS DE DNA ESPECIFICAS DE UN BANCO DE GENES DE B. BURGDORFERI CON METODOS DE BUSQUEDA APROPIADOS Y SE REPRESENTARON DIRECTAMENTE MEDIANTE LA AMPLIFICACION DEL DNA CON PRUEBAS DE HIDRURACION SELECCIONADAS Y BAJO EL CONTROL DE PROMOTORES INDUCIBLES COMO POR EJEMPLO EL PROMOTOR LAC. MEDIANTE LA DESCRIPCION DE PROCEDIMIENTOS DE LIMPIEZA EFICIENTES PARA LOS ANTIGENOS EXPRIMIDOS, SE PUDIERON DISPONER LAS PROTEINAS EN LA FORMA APROPIADA. CON ESTAS PROTEINAS SE PUEDEN CONFECCIONAR KITS DE PRUEBA ESPECIFICOS Y DIAGNOSTICOS SENSITIVOS. MEDIANTE LA COMBINACION SELECTIVA DE LAS PROTEINAS ACTIVAS INMUNOLOGICAMENTE ES POSIBLE UN DIAGNOSTICO PRECISO. ADEMAS, SE GENERARON ANTICUERPOS MONOCLONALES, QUE ENCUENTRAN APLICACION COMO REACTANTES PARA LA PRUEBA DE EXCITACION DIRECTAMENTE DE PRUEBAS DE EXAMEN Y DESPUES DEL CULTIVO. LAS SECUENCIAS DE DNA ESPECIFICAS DE LA BORRELIA BURGDORFERI SE PUEDEN APLICAR EN PRUEBAS DE PACIENTES PARA LA DEMOSTRACION DIRECTA DEL EXCITANTE (P.EJ. MEDIANTE REACCION PCR).
ES91902687T 1989-12-22 1990-12-21 Proteinas inmunologicamente activas de borrelia burgdorferi, estuches de ensayo relacionados y vacuna. Expired - Lifetime ES2092560T5 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE3942728 1989-12-22
DE3942728A DE3942728C1 (en) 1989-12-22 1989-12-22 New immunologically active proteins derived from Borelia burgdorferiensity polyethylene vessel and a high density polyethylene sealing cap - useful as vaccine and for quick accurate diagnosis of Borelia infections
DE4018988A DE4018988C2 (de) 1990-06-13 1990-06-13 Immunologisch aktive Proteine von Borrelia burgdorferi, Testkits, die diese Proteine enthalten und zum Nachweis von Antikörpern in Untersuchungsflüssigkeiten geeignet sind, monoklonale Antikörper, die gegen die immunologisch aktiven Proteine gerichtet sind und die Verwendung dieser Proteine als Impfstoffe gegen durch Borrelia-Stämme hervorgerufene Infektionen
DE4018988 1990-06-13

Publications (2)

Publication Number Publication Date
ES2092560T3 true ES2092560T3 (es) 1996-12-01
ES2092560T5 ES2092560T5 (es) 2004-09-16

Family

ID=25888425

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91902687T Expired - Lifetime ES2092560T5 (es) 1989-12-22 1990-12-21 Proteinas inmunologicamente activas de borrelia burgdorferi, estuches de ensayo relacionados y vacuna.

Country Status (9)

Country Link
US (5) US6248538B1 (es)
EP (1) EP0506868B2 (es)
AT (1) ATE140461T1 (es)
AU (1) AU7058691A (es)
CA (1) CA2072008C (es)
DE (1) DE59010422D1 (es)
DK (1) DK0506868T4 (es)
ES (1) ES2092560T5 (es)
WO (1) WO1991009870A1 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143872A (en) * 1988-10-24 2000-11-07 Symbicom Aktiebolag Borrelia burdorferi Osp A and B proteins and immunogenic peptides
US5777095A (en) * 1988-10-24 1998-07-07 Symbicom Aktiebolag Osp A and B Sequence of Borrelia burgdonferi strains ACA1 and IP90
DE4015911A1 (de) * 1989-09-19 1991-03-28 Max Planck Gesellschaft Impfstoff gegen die lyme-krankheit
CA2072008C (en) * 1989-12-22 2003-01-28 Renate Fuchs Immunologically active proteins from borrelia burgdorferi, related test kits which contain these proteins and are suitable for detecting antibodies in test fluids, and the use of these proteins as vaccines against infections caused by borrelia strains
HU216204B (hu) * 1990-06-15 1999-05-28 MTA Műszaki Fizikai és Anyagtudományi Kutatóintézet Eljárás és berendezés kis mágneses terek és térváltozások mérésére, valamint magnetométer szonda
JPH06501382A (ja) * 1990-06-15 1994-02-17 エール ユニバーシティ ライム病の予防および診断に用いる組成物および方法
DE4120345C5 (de) * 1991-06-19 2004-08-12 Arnold Prof. Dr.med. Vogt Proteinfragmente aus dem mittleren Bereich des Flagellins von Borrelia burgdorferi, geeignet als Antigene zum spezifischen Antikörpernachweis sowie Verfahren zu ihrer Herstellung
US6221363B1 (en) * 1991-07-11 2001-04-24 Baxter Aktiengesellschaft Vaccine for the prevention of lyme disease
US6872550B1 (en) 1991-07-11 2005-03-29 Baxter Vaccine Ag Immunogenic formulation of OspC antigen vaccines for the prevention and treatment of lyme disease and recombinant methods for the preparation of such antigens
US6676942B1 (en) * 1991-08-15 2004-01-13 Smithkline Beecham Biologicals (S.A.) Osp a proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
WO1993008299A1 (en) * 1991-10-18 1993-04-29 Connaught Laboratories Inc. Preparation of recombinant borrelia proteins
CA2123121A1 (en) * 1991-11-12 1993-05-27 Anthony C. Caputa Recombinant vaccine against lyme disease
US5618533A (en) * 1992-02-11 1997-04-08 Yale University Flagellin-based polypeptides for the diagnosis of lyme disease
EP0643586A4 (en) * 1992-05-26 1996-06-26 Smithkline Beecham Corp COMPOSITIONS FOR USE IN THE DIAGNOSIS AND PROPHYLAXIS OF LYME DISEASE.
WO1994013810A1 (en) * 1992-12-16 1994-06-23 The University Of Melbourne A proteinase inhibitor, precursor thereof and genetic sequences encoding same
US6716591B1 (en) 1993-07-30 2004-04-06 Yale University B. burgdorferi polypeptides
US5656451A (en) * 1993-07-30 1997-08-12 Yale University OspE, OspF, and S1 polypeptides in borrelia burgdorferi
US6248562B1 (en) 1993-11-01 2001-06-19 Research Foundation State University Of New York Chimeric proteins comprising borrelia polypeptides and uses therefor
US7008625B2 (en) 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
US5620862A (en) * 1993-11-24 1997-04-15 University Of Connecticut Methods for diagnosing early Lyme disease
US6251405B1 (en) 1995-06-07 2001-06-26 Connaught Laboratories, Inc. Immunological combination compositions and methods
ZA964896B (en) 1995-06-07 1997-01-08 Connaught Lab Expression of lipoproteins
US6716574B2 (en) 1996-05-02 2004-04-06 Dako A/S Osp-C derived peptide fragments
CA2294701C (en) 1997-06-30 2009-09-08 The Administrators Of The Tulane Educational Fund Surface antigens and proteins useful in compositions for the diagnosis and prevention of lyme disease
US6224882B1 (en) 1997-11-07 2001-05-01 Protein Science Corp. Insect cells or fractions as adjuvant for antigens
US6475492B1 (en) 1999-04-28 2002-11-05 The Administrators Of The Tulane Educational Fund Peptides and assays for the diagnosis of lyme disease
WO2002016421A2 (en) 2000-08-18 2002-02-28 Research Foundation Of The State University Of New York Altered ospa of borrelia burgdorferi
WO2009003492A1 (en) 2007-07-03 2009-01-08 Dako Denmark A/S Mhc multimers, methods for their generation, labeling and use
AU2002247905A1 (en) * 2002-03-28 2003-10-13 Markus Fritzsche Antibody against an epitope of the b. burgdorferi flagellar basal rod protein (fbrp)
US20040033623A1 (en) * 2002-08-16 2004-02-19 Igenex, Inc. Assay for detection of antigen in bodily fluid
CN101516905A (zh) 2006-09-15 2009-08-26 英特塞尔股份公司 疏螺旋体属抗原
EP2361930A3 (en) 2007-03-26 2011-10-26 Dako Denmark A/S Multimers of MHC-peptide complexes and uses thereof in Borrelia infectious diseases
EP2197908A2 (en) 2007-09-27 2010-06-23 Dako Denmark A/S Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics
DK2254592T3 (da) 2008-02-28 2019-09-09 Dako Denmark As MHC-multimerer til Borrelia-diagnostik og sygdom
EP2711021B1 (en) 2008-05-02 2016-03-09 BliNK Therapeutics Limited Products and methods for stimulating an immune response
WO2010009735A2 (en) 2008-07-23 2010-01-28 Dako Denmark A/S Combinatorial analysis and repair
GB0817244D0 (en) 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
EP2199303B1 (de) 2008-12-12 2013-06-05 Euroimmun Medizinische Labordiagnostika AG Polypeptide und Verfahren zur spezifischen Detektion von Antikörpern bei Patienten mit einer Borrelieninfektion
WO2011110953A2 (en) 2010-03-09 2011-09-15 Artemev, Timur Polyepitope constructs and methods for their preparation and use
US8142050B2 (en) 2010-06-24 2012-03-27 Mitutoyo Corporation Phosphor wheel configuration for high intensity point source
WO2012023033A2 (en) 2010-08-18 2012-02-23 Purdue Pharma L.P. Improved peptide immunogens
US10100092B2 (en) 2011-11-03 2018-10-16 Vca, Inc. Compositions and methods to detect various infectious organisms
WO2023240124A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Pseudotyped viral particles for targeting tcr-expressing cells
WO2023240109A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Multispecific molecules for modulating t-cell activity, and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4888276A (en) 1986-06-26 1989-12-19 Minnesota Mining And Manufacturing Company Method and composition for the diagnosis of Lyme disease
CA2072008C (en) * 1989-12-22 2003-01-28 Renate Fuchs Immunologically active proteins from borrelia burgdorferi, related test kits which contain these proteins and are suitable for detecting antibodies in test fluids, and the use of these proteins as vaccines against infections caused by borrelia strains
US5620862A (en) 1993-11-24 1997-04-15 University Of Connecticut Methods for diagnosing early Lyme disease

Also Published As

Publication number Publication date
DE59010422D1 (de) 1996-08-22
ATE140461T1 (de) 1996-08-15
AU7058691A (en) 1991-07-24
EP0506868B2 (de) 2004-02-11
US6248538B1 (en) 2001-06-19
EP0506868B1 (de) 1996-07-17
CA2072008A1 (en) 1991-06-23
US6509019B1 (en) 2003-01-21
US7083792B2 (en) 2006-08-01
US20030157562A1 (en) 2003-08-21
WO1991009870A1 (de) 1991-07-11
DK0506868T4 (da) 2004-04-26
CA2072008C (en) 2003-01-28
ES2092560T5 (es) 2004-09-16
DK0506868T3 (da) 1996-08-12
EP0506868A1 (de) 1992-10-07
US6753183B2 (en) 2004-06-22
US20040253611A1 (en) 2004-12-16
US6183755B1 (en) 2001-02-06

Similar Documents

Publication Publication Date Title
ES2092560T3 (es) Proteinas inmunologicamente activas de borrelia burgdorferi, estuches de ensayo relacionados y vacuna.
Adler et al. Effect of age upon primary alloantigen recognition by mouse spleen cells
ES2132395T3 (es) Especificidad lisosomica de inmunogenos.
SE8701413D0 (sv) Expression and purification of an htlv-iii gag/env gene protein
NO179106C (no) Fremgangsmåte for fremstilling av og ekspresjonssystem som koder for og kan uttrykke et rekombinant proteinkompleks med humanfaktor V111:C-aktivitet
CY1113247T1 (el) Νουκλεϊνικα οξεα με τιτλο 273ρ4β7 και η χρηση τους στην ανιχνευση καρκινου
FI93310C (fi) Menetelmä rokotteen valmistamiseksi piluksia kantavien nisäkkään kudoksiin tarttuvien bakteerien aiheuttamia tauteja vastaan
SE9102976D0 (sv) Hybrid dna vektorer, encelliga organismer och bakterier till anvaendning foer produktion av hiv-proteiner och peptider
CY1109837T1 (el) Διαγνωστικο και θεραπευτικο επιτοπιο
ES2130121T3 (es) Antigeno intra-acrosomico de esperma humano para uso en una vacuna anticonceptiva.
ES553757A0 (es) Un metodo para preparar proteinas que son inmunologicamente reactivas con anticuerpos para virus asociados con linfadenopatia
ES2144399T3 (es) Clonado del adn de virus de anemia de los pollos.
EP0346022B1 (en) Peptide fragments of HIV
GT197854594A (es) Vacuna contra haemophilus influenzae
ES2054769T3 (es) Polipeptidos hiv-2 recombinantes.
AR004567A1 (es) Metodos para detectar la infeccion de t.cruzi, en una muestra biologica, un vector de expresion recombinante, un microorganismo modificado, un kit de diagnostico, una composicion farmaceutica, el uso de la composicion farmaceutica para la preparacion de un medicamento para estimular la produccion de anticuerpos que se liguen a t. cruzi.
WO1991001996A1 (en) Peptide fragments of hiv
ATE124420T1 (de) Impfstoffe und testsätze für haemophilus influenzae.
ATE106945T1 (de) Methoden und materialien für die hiv-erkennung und therapie.
RU2334235C2 (ru) Способ картирования и устранения эпитопов т-клеток
ES2166757T3 (es) Secuencias de adn del virus de epstein-barr que codifican un antigeno de la capsida del virus de interes diagnostico, clones de expresion obtenidos por la reaccion en cadena de la polimerasa y el uso de este antigeno recombinante en ensayos de diagnostico.
Velasquez Pulgarin et al. Light induced expression of gRNA allows for optogenetic gene editing of T lymphocytes in vivo
Lubeck et al. Multiplication of bovine parvovirus in two cell strains
AR116975A1 (es) Tratamiento de pacientes con nsclc refractarios al anticuerpo anti-pd-1
Umoh et al. Antigenic Characterization of Street Rabies Virus Isolates from Nigeria Using Monoclonal Antibodies 1

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 506868

Country of ref document: ES